Real-world data indicates that sarcoidosis caused by immune checkpoints or BRAF/MEK inhibitors occurs more frequently than reported in Phase 3 melanoma clinical trials [6, 7]. This evidence concerns the gene MAP2K7 and sarcoidosis.